Vignette 1: The "Treatment-Resistant Depression" That Was Not Unipolar

Dr. Reyes, a family medicine physician, has been managing Maria, a 31-year-old bilingual administrative assistant, for recurrent major depression for seven years. Maria first presented at age 24 with a severe depressive episode following a breakup. Since then, she has tried sertraline, escitalopram, venlafaxine, and bupropion, each producing partial improvement followed by relapse within months. She is now on her fifth antidepressant trial (duloxetine) and reports feeling "flat and hopeless."

On closer review, Dr. Reyes notes that Maria's depression onset was before age 25 (Section 5.3: early onset is a conversion predictor with Hedges' g = -0.33). She has had at least five depressive episodes in seven years (Section 5.3: four or more episodes is the highest-ranking predictor of bipolarity). Her mother has Bipolar II disorder (Section 5.3: family history yields OR 2.89 for conversion). When Dr. Reyes asks about times Maria felt "the opposite of depressed," Maria describes two periods, each lasting about a week, where she felt "amazing," slept only four hours, took on multiple projects at work, and spent excessively. She did not report these because she considered them "her normal self" returning.

Maria screens positive on the Mood Disorder Questionnaire (MDQ). Dr. Reyes refers her to psychiatry, where she is diagnosed with Bipolar II Disorder. Her antidepressant is tapered and lamotrigine is initiated as maintenance treatment (the specific rationale for medication selection in BD-II is covered in Module 4). Over the following year, her depressive episodes are substantially reduced.

Teaching points: This vignette illustrates the typical diagnostic delay (Section 5.2: mean 5.6 years for patients whose first episode is depressive). Maria's case demonstrates three independent predictors of bipolarity (early onset, high recurrence, family history). Her hypomanic episodes were not reported because patients frequently experience hypomania as a welcome relief from depression and do not spontaneously identify it as pathological (Section 1.2). The vignette reinforces why collateral history and systematic screening are essential (Section 5.3: Clinical Pearl). Note: in many practice settings, particularly rural and underserved areas, psychiatric referral involves months-long waitlists or is unavailable entirely. Module 2 provides a step-by-step evaluation framework that PCPs and other non-psychiatrist clinicians can use to initiate appropriate management while awaiting specialist evaluation, including when it is appropriate to begin mood-stabilizing treatment in primary care.

Vignette 2: The Adolescent Diagnostic Dilemma

Tyler, a 16-year-old, is referred to a child and adolescent psychiatrist by his school counselor for "behavioral problems." Over the past year, Tyler's grades have dropped from As to Ds, he has been suspended twice for verbal outbursts toward teachers, and his parents report increasingly volatile mood at home, alternating between explosive irritability and periods of withdrawal.

The differential includes ADHD, major depression, and bipolar disorder. The psychiatrist notes that Tyler's irritability is not chronic and persistent (as it would be in ADHD or Disruptive Mood Dysregulation Disorder) but occurs in discrete episodes lasting several days to a week, during which he also sleeps only 3 to 4 hours a night, talks rapidly, and starts ambitious projects he does not complete. Between these episodes, he is either euthymic or depressed. His maternal uncle has Bipolar I disorder.

The episodic pattern distinguishes this from ADHD (Section 1, and cross-reference ADHD Module 2: the key differentiator is episodicity versus persistence). The decreased need for sleep, rather than difficulty sleeping, is one of the most reliable symptoms distinguishing mania/hypomania from ADHD-related sleep problems. Family history of Bipolar I and the episodic, discrete nature of the mood elevation raise strong suspicion for Bipolar I Disorder, current episode manic, with predominantly irritable rather than euphoric mood. Before confirming this diagnosis, the psychiatrist would complete a medical workup (including thyroid function and toxicology screening), obtain detailed collateral history from parents and school, and consider structured diagnostic assessment, as described in Module 2.

Teaching points: In adolescents, mania frequently presents as severe irritability rather than euphoria (Section 1.1: irritable mood is an alternative Criterion A presentation). The critical diagnostic feature is episodicity: ADHD is persistent across settings and stable over time; bipolar disorder produces distinct episodes with clear onset and offset. The DSM-5-TR requires four Criterion B symptoms when the predominant mood is irritable (versus three when euphoric). Tyler's family history (Section 3.1: bipolar disorder's heritability of 80-85% means first-degree relatives carry substantially elevated risk, estimated at approximately 10% absolute risk compared to 1-2% in the general population) and sleep pattern (decreased need for sleep, not insomnia) point toward bipolarity.

Vignette 3: "I Feel Fine, Why Do I Need Medication?"

Priya, a 28-year-old marketing professional, was diagnosed with Bipolar I disorder two years ago after a manic episode requiring hospitalization. She was stabilized on lithium and has been euthymic for 18 months. At her quarterly appointment, she tells her NP that she wants to stop lithium because "I feel completely normal" and is frustrated by the blood monitoring and mild hand tremor.

The NP uses the longitudinal course data to frame the conversation (Section 6): patients with BD-I are symptomatic approximately 47% of their follow-up time in the NIMH CDS data, with depression dominating 3:1 over mania. In STEP-BD, 58.4% of patients who achieved "recovery" relapsed within two years. The kindling model (Section 4.1) suggests that each subsequent episode lowers the threshold for future episodes, and preclinical evidence suggests lithium may have neuroprotective properties, including effects on gene expression that could slow the kindling process. Lithium also has the strongest meta-analytic evidence of any mood stabilizer for reducing suicide risk, which is discussed as a factor in the treatment decision.

Priya and her NP agree to continue lithium with a plan to reassess in six months. The NP also discusses the cognitive subgroup data (Section 6.4): approximately one-third of patients maintain good cognitive function, and this outcome is associated with lower episode burden, making episode prevention a cognitive protection strategy.

Teaching points: This vignette illustrates the medication adherence challenge that affects approximately 40% to 50% of bipolar patients, with non-adherence rates of 30-50% consistently reported across studies and a median duration of continuous lithium adherence of just 72 days in one US study *(Jawad et al., 2018, Ther Adv Psychopharmacol, 8(12), 349-363; Sajatovic et al., 2007, Psychiatr Serv, 58(6), 855-863).* The NP uses the concepts from this module --- that untreated episodes make the brain more vulnerable over time and that mood stabilizers may protect against this progressive damage --- to reframe medication adherence not as compliance with authority but as self-protection. The conversation translates the neuroscience (kindling, neuroprotection, cognitive outcomes) into patient-accessible language, modeling how Module 1 content informs the exam room conversation without expecting clinicians to use molecular terminology with patients. Module 3 covers the practical management of lithium side effects and monitoring.

Key Takeaways for Clinical Practice

1. Bipolar disorder is a systems-level brain circuit disorder, not a simple chemical imbalance. The core model involves failed prefrontal cortical regulation over hyperactive limbic and reward-processing structures (amygdala, ventral striatum). This circuit dysfunction is trait-like, persisting between episodes, which explains why ongoing treatment matters even during euthymia. Understanding this model gives clinicians a framework for explaining the illness to patients and families that is accurate and destigmatizing. (Section 2)

2. Bipolar II is not "bipolar lite." BD-II patients spend far more time depressed than BD-I patients (depression-to-hypomania ratio ranging from 3.8:1 to as high as 37:1 in the NIMH CDS data, depending on analysis subset). Cognitive impairment, functional disability, and suicide risk are at least equivalent to BD-I. Calling BD-II "milder" risks under-treatment. (Sections 1.2, 6.1)

3. The bipolar-unipolar boundary is the most consequential diagnostic question in mood disorders. Approximately 6% of patients in population registries and over 20% in clinical cohorts initially diagnosed with MDD are eventually rediagnosed as bipolar (up to 40% in the most closely monitored populations). The average diagnostic delay is 5 to 10 years. During this delay, antidepressant monotherapy can destabilize mood, accelerate cycling, and increase suicide risk. (Section 5)

4. Five clinical features should trigger screening for bipolarity in any depressed patient: family history of bipolar disorder, age of onset before 25, four or more depressive episodes, psychotic features during depression, and any history of mood elevation on an antidepressant. A "yes" to any of these warrants systematic screening with the MDQ or HCL-32 and the active pursuit of collateral history. (Section 5.3)

5. For non-prescribing clinicians (therapists, school psychologists): You may be the first professional to notice patterns suggestive of bipolarity, including escalating mood volatility, sleep pattern changes, or behavioral shifts that look episodic rather than chronic. You are also likely to observe hypomania before the prescriber does, because you see the patient more frequently and in more natural conversation. Know the five-question screen (Section 5.3) and communicate concerns to the prescribing provider. In adolescents, the critical distinction is episodicity versus chronicity: ADHD and DMDD produce persistent symptoms; bipolar disorder produces distinct episodes. (Sections 1, 5)

6. The kindling model provides the strongest argument for early, sustained treatment. Each untreated mood episode lowers the threshold for the next. Preclinical evidence suggests lithium and valproate may have neuroprotective properties beyond acute mood stabilization, including effects on gene expression and cellular resilience through HDAC inhibition. If confirmed in clinical studies, this would position mood stabilizers as potential disease-modifying agents, not merely symptom managers. Explaining this emerging evidence to patients reframes medication adherence as self-protection rather than compliance. (Section 4.1)

7. Sleep is a therapeutic target, not a lifestyle recommendation. Circadian rhythm disruption is a central pathogenic driver of bipolar disorder, with clock gene polymorphisms creating inherent vulnerability and sleep disruption serving as both a prodrome and a trigger for mood episodes. Interpersonal and Social Rhythm Therapy (IPSRT) directly targets this pathway. Clinicians should counsel all bipolar patients that protecting sleep regularity is a core treatment strategy. (Section 4.2)

8. Bipolar disorder carries one of the highest suicide risks of any psychiatric disorder. The SMR for suicide is 47.0 in patients under age 30. Up to 73.5% of first life-threatening suicide attempts occur during the diagnostic delay before mood-stabilizing treatment is initiated. The majority of suicides occur during depressive or mixed episodes. Comorbid substance use (OR=3.02) and prior attempts (OR=2.38) are the strongest risk amplifiers. Lithium has the strongest meta-analytic evidence of any mood stabilizer for reducing suicide risk (Cipriani et al., 2013, BMJ, 346, f3646) (Sections 5.2, 6.6)

What Comes Next: From Recognition to Action

This module has given you the neuroscience foundation: what bipolar disorder is at the level of circuits and genes, how it is classified, how it progresses, and why the bipolar-unipolar boundary matters. If you have identified a patient you suspect may have bipolar disorder using the tools in this module (the five-question heuristic, the conversion predictors, the episodicity distinction), Module 2 provides the step-by-step clinical evaluation framework, including structured screening instruments with interpretation guidance, the differential diagnosis workup (ADHD, BPD, DMDD, substance-induced mood disorders, medical causes), and practical guidance for what to do when psychiatric referral is not immediately available.

Key References

Starred (★) papers are recommended for clinicians who want to read further.

[NOTE: This reference list is a working draft assembled during Pass 1. References are listed in the format extractable from source documents. Full bibliographic details (volume, issue, pages) will be verified and completed during Pass 15 (Citation Integrity). References marked with ★ are recommended for further reading.\]

★ APA. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.

★ Baldessarini, R.J., Tondo, L., & Hennen, J. (2003). Treatment-latency and previous episodes: relationships to pretreatment morbidity and response to maintenance treatment in bipolar I and II disorders. Bipolar Disord, 5(3), 169-179.

Baldessarini, R.J., Tondo, L., & Hennen, J. (1999). Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry, 60(Suppl 2), 77-84.

Baldessarini, R.J., Tondo, L., & Hennen, J. (1999). Treatment delays in bipolar disorders [letter]. Am J Psychiatry, 156(5), 811-813.

Cha, B., Kim, J.H., Ha, T.H., Chang, J.S., & Ha, K. (2009). Polarity of the first episode and time to diagnosis of bipolar I disorder. Psychiatry Investig, 6(2), 96-101.

Angst, J., et al. (2003). Toward a re-definition of subthreshold bipolarity. Arch Gen Psychiatry, 60(2), 163-172.

★ Bora, E. (2018). Neurocognitive profiling of adult bipolar disorder: a meta-analysis of clustering studies. Eur Neuropsychopharmacol, 28(1), 64-74.

Bora, E., et al. (2009). Cognitive endophenotypes of bipolar disorder: a meta-analysis. Psychol Med, 39(6), 971-982.

★ Ferreira, M.A., et al. (2008). Genome-wide association identifies ANK3 and CACNA1C. Nat Genet, 40(9), 1056-1058.

★ Grotzinger, A.D., et al. (2025). The landscape of shared and divergent genetic influences across psychiatric disorders. Nature.

Hirschfeld, R.M., et al. (2003). Perceptions and impact of bipolar disorder. J Clin Psychiatry, 64(2), 161-174.

★ Judd, L.L., et al. (2002). Long-term natural history of bipolar I disorder. Arch Gen Psychiatry, 59(6), 530-537.

★ Judd, L.L., et al. (2003). Natural history of bipolar II disorder. Arch Gen Psychiatry, 60(3), 261-269.

Kendler, K.S., et al. (1995). Genetic risk factors for major psychiatric disorders. Am J Psychiatry, 152(6), 901-904.

★ Kessing, L.V., et al. (2017). Diagnostic conversion to bipolar disorder. Bipolar Disord, 19(4), 261-267.

Kieseppa, T., et al. (2004). High concordance of bipolar I disorder in twins. Am J Psychiatry, 161(10), 1814-1821.

McGuffin, P., et al. (2003). Heritability of bipolar affective disorder. Arch Gen Psychiatry, 60(5), 497-502.

Mertens, J., et al. (2015). Differential responses to lithium in hyperexcitable neurons. Nature, 527(7576), 95-99.

★ Mullins, N., et al. (2021). Genome-wide association study of more than 40,000 bipolar disorder cases. Nat Genet, 53(6), 817-829.

Post, R.M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry, 149(8), 999-1010.

★ Ratheesh, A., et al. (2017). Prospective transition from MDD to bipolar disorder. Acta Psychiatr Scand, 135(4), 273-284.

Sachs, G.S., et al. (2007). Adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356(17), 1711-1722.

Sullivan, P.F., et al. (2000). Genetic epidemiology of major depression. Am J Psychiatry, 157(10), 1552-1562.

★ Tondo, L., et al. (2024). Antidepressant-associated diagnostic change in depression. Acta Psychiatr Scand, 149(1), 60-70.

Tondo, L. & Baldessarini, R.J. (2014). Factors predicting bipolar diagnosis. J Affect Disord, 168, 290-295.

★ Yatham, L.N., et al. (2018). CANMAT and ISBD guidelines for bipolar disorder. Bipolar Disord, 20(2), 97-170.

NICE. (2014, updated 2023). Bipolar disorder: assessment and management. Clinical Guideline CG185.

Karanti, A., et al. (2020). Characteristics of bipolar I and II disorder. Bipolar Disord, 22(4), 392-400.

İlhan, R.S., et al. (2025). Cognitive differences between BD-I and BD-II. Front Psychiatry, 16.

McIntyre, R.S., et al. (2020). Bipolar disorder. Lancet, 396(10265), 1841-1856.

Oglodek, E.A., et al. (2025). Molecular and neuroimaging correlates of bipolar disorder. Int J Mol Sci.

Harrison, P.J., et al. (2018). The emerging neurobiology of bipolar disorder. Trends Neurosci, 41(1), 18-30.

Hafeman, D.M., et al. (2025). Person-level contributions of bipolar polygenic risk score to the prediction of new-onset bipolar disorder in at-risk offspring. J Affect Disord, 368, 359-365.

Liu, X., Agerbo, E., Li, J., Meltzer-Brody, S., Bergink, V., & Munk-Olsen, T. (2017). Depression and anxiety in the postpartum period and risk of bipolar disorder: A Danish nationwide register-based cohort study. J Clin Psychiatry, 78(5), e469-e476.

Chen, C.H., et al. (2011). A quantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord, 13(1), 1-15.

Chen, P.H., Tsai, S.Y., Pan, C.H., et al. (2025). Risk profiles before suicide mortality in patients with bipolar disorder across the lifespan. Eur Psychiatry.

Townsend, J.D. & Altshuler, L.L. (2012). Emotion processing and regulation in bipolar disorder. Psychiatr Clin North Am, 35(2), 357-369.

Alloy, L.B., et al. (2016). Role of reward sensitivity and processing in major depressive and bipolar spectrum disorders. Behav Ther, 47(5), 600-621.

Angst, J., et al. (2011). Toward a re-definition of subthreshold bipolarity (BRIDGE study). Arch Gen Psychiatry, 68(8), 791-798.

Berk, M., et al. (2011). Neuroprogression in bipolar disorder. Neurosci Biobehav Rev, 35(3), 804-817.

Calabrese, J.R., et al. (2005). Valproate in rapid cycling bipolar disorder. Am J Psychiatry, 162(11), 2152-2161.

Cipriani, A., et al. (2013). Lithium in the prevention of suicide in mood disorders. BMJ, 346, f3646.

Dunner, D.L. & Fieve, R.R. (1974). Clinical factors in lithium prophylaxis failure. Arch Gen Psychiatry, 30(2), 229-233.

Fornaro, M., et al. (2020). NNT for antipsychotics in bipolar depression. J Affect Disord, 266, 730-743.

Jacobsen, F.M. (1993). Low-dose valproate for cyclothymia. J Clin Psychiatry, 54(1), 33-34.

Kim, W., et al. (2020). Diagnostic conversion from MDD to bipolar disorder. Bipolar Disord, 22(8), 844-850.

Koukopoulos, A., et al. (2013). Mixed features in depression. J Affect Disord, 150(1), 65-71.

Malhi, G.S., et al. (2020). Mixed features specifier controversy. Bipolar Disord, 22(4), 332-340.

Novick, D.M., Swartz, H.A., & Frank, E. (2010). Suicide attempts in bipolar I and II. Bipolar Disord, 12(1), 1-9.

Perlis, R.H., et al. (2006). Predictors of recurrence in bipolar disorder. Am J Psychiatry, 163(2), 217-224.

Perugi, G., et al. (2015). Cyclothymia and borderline personality disorder. Curr Psychiatry Rep, 17(5), 34.

★ Schneck, C.D., et al. (2008). The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry, 165(3), 370-377.

Takeshima, M. & Oka, T. (2015). DSM-5 mixed features specifier sensitivity. Psychiatry Clin Neurosci, 69(1), 1-9.

Van Meter, A.R., et al. (2012). Cyclothymia prevalence. Clin Psychol Rev, 32(8), 711-721.

Vieta, E. & Suppes, T. (2008). Bipolar II disorder diagnosis. J Clin Psychiatry, 69(12), 1890-1891.

Judd, L.L., et al. (2002). Time to recovery in bipolar I disorder. Arch Gen Psychiatry, 59(6), 530-537.

Kessing, L.V., et al. (2017). Diagnostic conversion from MDD to bipolar disorder. Bipolar Disord, 19(4), 261-267.

Rhee, T.G., et al. (2023). Diagnostic conversion from MDD to bipolar disorder. Psychol Med, 53(1), 22-31.

Dagani, J., et al. (2017). Duration of untreated illness in bipolar disorder. Br J Psychiatry, 210(3), 188-196.

PsychHQ

Clinical Vignettes & Key Takeaways